Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07570992 | A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM | PHASE1 | RECRUITING | 80 | — | — | May 4, 2026 | Jun 25, 2028 | May 19, 2026 | 1 | Austria |
Measured in events.
| Arm | Type | Description |
|---|---|---|
| NNC1679-0001 | EXPERIMENTAL | Participants will receive NNC1679-0001 subcutaneously. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to NNC1679-0001 s.c. |
| Name | Type | Description |
|---|---|---|
| NNC1679-0001 | DRUG | NNC1679-0001 will be administered subcutaneously. |
| Placebo | DRUG | Placebo will be administered subcutaneously. |
Inclusion Criteria: All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male or female (sex at birth) of nonchildbeari...